Skip to main content

Table 1 Demographic, clinical, laboratory and articular characteristics at start of treatment in PedACR 30 responders and non- responders at month 3, PedACR 70 responders and non-responders at month 12

From: Predictors of response to methotrexate in juvenile idiopathic arthritis

Parameter PedACR 30 at 3 months (n = 731) PedACR 70 at 12 months (n = 707)
  Responder Non responder Responder Non responder
  566 (77.4%) 165 (22.6%) 466 (65.9%) 241 (34.1%)
Gender, female 386 (68.2%) 116 (70.3%) 318 (68.2%) 172 (71.4%)
Systemic onset JIA 21 (84%) 4 (16%) 13 (76.5%) 4 (23.5%)
RF-negative polyarthritis 162 (81%) 38 (19%) 135 (70.3%) 57 (29.7%)
RF-positive polyarthritis 18 (81.8%) 4 (18.2%) 16 (69.6%) 7 (30.4%)
Persistent oligoarthritis 159 (76.8%) 48 (23.2%) 145 (67.4%) 70 (32.6%)
Extended oligoarthritis 71 (73.9%) 25 (26.1%) 63 (66.3%) 32 (33.7%)
Enthesitis related arthritis 66 (72.5%) 25 (27.5%) 52 (61.9%) 32 (38.1%)
Psoriatic arthritis 55 (76.4%) 17 (23.6%) 34 (50.7%)** 33 (49.3%)
unclassified JIA 14 (77.8%) 4 (22.2%) 8 (57.1%) 6 (42.9%)
Age at onset of disease (years) 6.8 (3.3-11) 6.4 (3.8-10.5) 6.1 (2.9-10.4)** 8.6 (3.9-12.1)
Age at MTX start (years) 9.7 (5.3-13.5) 9.5 (6–13.3) 8.5 (4.8-13)*** 11.4 (6.8-14.5)
Disease duration before MTX start (years) 0.9 (0.3-2.9) 1.1 (0.4-3.2) 0.6 (0.3-2.3)*** 1.3 (0.5-3.4)
Concomitant use of NSAID 514 (90.8%)** 149 (90.3%) 430 (92.3%) 221 (91.7%)
Physician’s global assessment of disease activity 40 (25–65)*** 29 (19–51.7) 45 (26–67)*** 30 (20–55)
Parent’s global assessment of overall well-being 44 (19–61)*** 27 (8–46) 42 (20–59)** 31.5 (10–57)
Parents evaluation of child’s pain 40 (15–60.2)** 26.5 (4.2-53) 40 (17.2-58.7)** 29.5 (5–56.25)
CHAQ-DI 0.5 (0.12-0.87)*** 0.25 (0–0.6) 0.5 (0.12-0.9)*** 0.25 (0–0.75)
HLA B27 positive 94 (19.2%) 35 (22.9%) 77 (19.4%) 42 (18.8%)
ANA positive 271 (49.2%) 76 (48.4%) 240 (53.7%) 117 (48.9%)
ESR (mm/h) 18 (10.0-31)*** 12 (6.0-23.5) 19.5 (10–36)*** 12 (6.5-24)
CRP (mg/dl) 4.2 (1.1-12) 3 (1–7) 5 (2–15.35)*** 3 (1–7)
No. of active joints 4 (2–8)*** 2 (1–3) 4 (2–8)*** 2 (1–5)
No of tender joints 3 (2–7)*** 2 (1–4 ) 3 (2–7)** 2 (1–6)
No. of swollen joints 4 (2–8)*** 2 (1–4) 3 (2–7)*** 2 (0–5)
No. of joints with LOM 4 (2–8)*** 2 (1–4) 4 (2–8)*** 2 (1–5)
Presence of morning stiffness 360 (63.6%)*** 71 (43%) 300 (64.4%)*** 120 (49.8%)
  1. Data are numbers (%) or median (first to third quartile). P-values of correlation with PedACR 30 or 70 are shown in column “responder”.
  2. **p < 0.01;***p < 0.001.